{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:08:52Z","timestamp":1788764932627,"version":"build-2803163510"},"reference-count":265,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.prp.2026.156645","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T06:47:33Z","timestamp":1786171653000},"page":"156645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future Directions"],"prefix":"10.1016","volume":"287","author":[{"given":"Arif","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Adnan","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ajazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib1","first-page":"583","article-title":"Assessment of CAR-T cells by the transparency committee of the french national authority for health (2018\u201323)","volume":"208","author":"Baba","year":"2024","journal-title":"Bull. Acad. Natl. Med."},{"issue":"11","key":"10.1016\/j.prp.2026.156645_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21113906","article-title":"CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large b-cell lymphomas","volume":"21","author":"Ahmad","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"26","key":"10.1016\/j.prp.2026.156645_bib3","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib4","first-page":"100","article-title":"\u201c\u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS Public Access","volume":"176","author":"MICHA","year":"2017","journal-title":"Physiol. Behav."},{"issue":"February","key":"10.1016\/j.prp.2026.156645_bib5","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: Next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"issue":"9","key":"10.1016\/j.prp.2026.156645_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1477-2574.2011.00344.x","article-title":"Engineered T cells for pancreatic cancer treatment","volume":"13","author":"Katari","year":"2011","journal-title":"Hpb"},{"key":"10.1016\/j.prp.2026.156645_bib7","article-title":"CAR T cells re-directed by a rationally designed human peptide tag demonstrate efficacy in preclinical models","volume":"00000","author":"Knelangen","year":"2025","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156645_bib9","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (Tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug. Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib10","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1634\/theoncologist.2019-0395","article-title":"Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist","volume":"25","author":"Jacobson","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.prp.2026.156645_bib11","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2026.156645_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"issue":"39","key":"10.1016\/j.prp.2026.156645_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","author":"Santomasso","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. B."},{"issue":"8","key":"10.1016\/j.prp.2026.156645_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.prp.2026.156645_bib15","series-title":"All rights reserved. For Permissions, please email: journals.permissions@oup.com","first-page":"1","article-title":"\u201c\u00a9 The Author 2015","author":"Walker","year":"2015"},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib16","first-page":"324","article-title":"Cancer immunotherapy with CAR-T cells - Behold the future","volume":"18","author":"Graham","year":"2018","journal-title":"Clin. Med. J. R. Coll. Physicians Lond."},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib17","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in car-t cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"8","key":"10.1016\/j.prp.2026.156645_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.2021012882","article-title":"A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies","volume":"140","author":"Klatt","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T Therapies in Solid Tumors: Opportunities and Challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"September","key":"10.1016\/j.prp.2026.156645_bib22","article-title":"Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies","volume":"68","author":"Arunachalam","year":"2024","journal-title":"Blood Rev."},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib23","article-title":"Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies","volume":"74","author":"Huang","year":"2024","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.prp.2026.156645_bib24","doi-asserted-by":"crossref","unstructured":"R. Zheng, X. Zhu, and Y. Xiao, \u201cAdvances in CAR-T-cell therapy in T-cell malignancies,\u201d pp. 1\u201319, 2024.","DOI":"10.1186\/s13045-024-01568-z"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156645_bib26","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/j.annonc.2024.08.857","article-title":"\u201c806MO Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL","volume":"35","author":"France","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jama.1993.03500010119052","article-title":"Annals of Oncology","volume":"269","author":"Bosl","year":"1993","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib28","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2026.156645_bib29","article-title":"CAR-T cell therapy for hematological malignancies: History, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2478\/ahp-2020-0002","article-title":"A brief history of car-t cells: From laboratory to the bedside","volume":"51","author":"Styczy\u0144ski","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"10.1016\/j.prp.2026.156645_bib31","doi-asserted-by":"crossref","unstructured":"Y. Chen, B. Abila, and Y.M. Kamel, \u201cCAR-T: What Is Next\u00a0?,\u201d 2023.","DOI":"10.3390\/cancers15030663"},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib32","article-title":"Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review","volume":"4","author":"Ahmad","year":"2022","journal-title":"Adv. Cancer Biol. - Metastas-.-."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00005-020-00599-x","article-title":"The Application of CAR-T Cells in Haematological Malignancies","volume":"68","author":"Skorka","year":"2020","journal-title":"Arch. Immunol. Ther. Exp. (Warsz. )."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156645_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489827","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors","volume":"15","author":"Khan","year":"2025","journal-title":"Front. Immunol."},{"issue":"February","key":"10.1016\/j.prp.2026.156645_bib38","first-page":"1","article-title":"In-depth analysis of the safety of CAR-T cell therapy for solid tumors","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156645_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: A scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib41","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12964-024-01995-y","article-title":"MDSC: a new potential breakthrough in CAR-T therapy for solid tumors","volume":"22","author":"Abdalsalam","year":"2024","journal-title":"Cell. Commun. Signal."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-6-1","article-title":"The potential and promise for clinical application of adoptive T cell therapy in cancer","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"22","key":"10.1016\/j.prp.2026.156645_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms252212201","article-title":"Significant Advancements and Evolutions in Chimeric Antigen Receptor Design","volume":"25","author":"Gaimari","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156645_bib44","doi-asserted-by":"crossref","unstructured":"P.Y. Lam et al., \u201cEnhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted,\u201d no. November 2024, 2025, doi: 10.1002\/ctm2.70140.","DOI":"10.1002\/ctm2.70140"},{"key":"10.1016\/j.prp.2026.156645_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1462697","article-title":"Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9","volume":"15","author":"Amiri","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CCO.0000000000001076","article-title":"Chimeric antigen receptor adoptive immunotherapy in central nervous system tumors: state of the art on clinical trials, challenges, and emerging strategies to addressing them","volume":"36","author":"Del Baldo","year":"2024","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-023-01430-8","article-title":"New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses","volume":"22","author":"Kamrani","year":"2024","journal-title":"Cell. Commun. Signal."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib48","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.7150\/jca.50509","article-title":"CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety","volume":"12","author":"Li","year":"2021","journal-title":"J. Cancer"},{"issue":"September","key":"10.1016\/j.prp.2026.156645_bib49","first-page":"1","article-title":"Recent advances in CAR-T cells therapy for colorectal cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.prp.2026.156645_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02081","article-title":"Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy","volume":"43","author":"Ouladan","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"ember","key":"10.1016\/j.prp.2026.156645_bib51","first-page":"1","article-title":"CAR T-cells for colorectal cancer immunotherapy: Ready to go?","volume":"13","author":"Ghazi","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jcyt.2023.01.009","article-title":"Generation of colon cancer\u2013derived tumor-infiltrating T cells (TILs) for adoptive cell therapy","volume":"25","author":"Albrecht","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.prp.2026.156645_bib53","first-page":"1","author":"Sawicki","year":"2021","journal-title":"Factors Dev. Symptoms Diagn.\u201d Mdpi no. March2021"},{"issue":"6382","key":"10.1016\/j.prp.2026.156645_bib54","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science (80-."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib55","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: The long and winding road to solid tumors review-article","volume":"9","author":"D\u2019Aloia","year":"2018","journal-title":"Cell. Death Dis."},{"issue":"7","key":"10.1016\/j.prp.2026.156645_bib57","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00262-012-1254-0","article-title":"Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges","volume":"61","author":"Lipowska-Bhalla","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"21","key":"10.1016\/j.prp.2026.156645_bib58","doi-asserted-by":"crossref","first-page":"11781","DOI":"10.3390\/ijms222111781","article-title":"Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells","volume":"22","author":"Aparicio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156645_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/9918116","article-title":"Colorectal Cancer: From Genetic Landscape to Targeted Therapy","volume":"2021","author":"El Bali","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.prp.2026.156645_bib60","article-title":"\u201cBases moleculares del cancer de colon,\u201d","author":"Ph. D","year":"2009","journal-title":"New. Engl. J. o F. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12094-018-02002-w","article-title":"SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)","volume":"21","author":"G\u00f3mez-Espa\u00f1a","year":"2019","journal-title":"Clin. Transl. Oncol."},{"issue":"July 2022","key":"10.1016\/j.prp.2026.156645_bib62","article-title":"CD166-specific CAR-T cells potently target colorectal cancer cells","volume":"27","author":"He","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.prp.2026.156645_bib63","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial","author":"Chen","year":"2024","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib64","article-title":"CAR-T Cell Therapy: Advances in Digestive system malignant tumors","volume":"32","author":"Xu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"6667","key":"10.1016\/j.prp.2026.156645_bib65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.add7034","article-title":"Probiotic-guided CAR-T cells for solid tumor targeting","volume":"382","author":"Vincent","year":"2023","journal-title":"Science (80-. )"},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yexcr.2014.04.007","article-title":"Carcinoembryonic antigen promotes colorectal cancer progression by targeting adherens junction complexes","volume":"324","author":"Bajenova","year":"2014","journal-title":"Exp. Cell. Res."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib67","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10555-020-09898-3","article-title":"Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?","volume":"39","author":"Gires","year":"2020","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib68","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms22126567","article-title":"MUC1: Structure, Function, and Clinic Application in Epithelial Cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"10","key":"10.1016\/j.prp.2026.156645_bib70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/17512433.2020.1826304","article-title":"An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer","volume":"13","author":"Rappaport","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"28","key":"10.1016\/j.prp.2026.156645_bib71","doi-asserted-by":"crossref","first-page":"17793","DOI":"10.1021\/acsami.6b04403","article-title":"Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles","volume":"8","author":"Ning","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7","article-title":"\u201cExpression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis,\u201d","volume":"184","author":"De Jong","year":"1998","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/gastro\/goaa026","article-title":"Anti-EGFR therapy in metastatic colorectal cancer: Mechanisms and potential regimens of drug resistance","volume":"8","author":"Li","year":"2020","journal-title":"Gastroenterol. Rep."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib74","first-page":"246","article-title":"Epidermal growth factor receptor as a therapeutic target in colorectal cancer","volume":"2","author":"Cohen","year":"2003","journal-title":"Clin. Colorectal Cancer"},{"issue":"22","key":"10.1016\/j.prp.2026.156645_bib75","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1158\/1078-0432.CCR-09-1678","article-title":"Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane\/dextran sulfate sodium model: Roles of transforming growth factor-\u03b1 and PTGS2","volume":"15","author":"Dougherty","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7407","key":"10.1016\/j.prp.2026.156645_bib76","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib77","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1357-2725(99)00015-1","article-title":"EGF receptor","volume":"31","author":"Wells","year":"1999","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib78","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1083\/jcb.200307137","article-title":"Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands","volume":"164","author":"Sahin","year":"2004","journal-title":"J. Cell. Biol."},{"issue":"18","key":"10.1016\/j.prp.2026.156645_bib79","first-page":"32S","article-title":"The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia","volume":"19","author":"Arteaga","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib80","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/jcp.1041390323","article-title":"EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration","volume":"139","author":"Grotendorst","year":"1989","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib81","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/0008-5472.CAN-05-3343","article-title":"Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis","volume":"67","author":"Fichera","year":"2007","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.prp.2026.156645_bib82","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-07-4926","article-title":"Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model","volume":"14","author":"Dougherty","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib83","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/path.1814","article-title":"Up-regulated expression of ADAM17 in human colon carcinoma: Co-expression with EGFR in neoplastic and endothelial cells","volume":"207","author":"Blanchot-Jossic","year":"2005","journal-title":"J. Pathol."},{"issue":"19","key":"10.1016\/j.prp.2026.156645_bib84","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1074\/jbc.C700185200","article-title":"HDAC6 is required for epidermal growth factor-induced \u03b2-catenin nuclear localization","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib85","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/156800909789271495","article-title":"Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy","volume":"9","author":"Veeken","year":"2009","journal-title":"Curr. Cancer Drug. Targets"},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib86","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/sj.onc.1209019","article-title":"Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1","volume":"25","author":"Chen","year":"2006","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib87","first-page":"181","article-title":"Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas","volume":"7","author":"Liu","year":"1992","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.prp.2026.156645_bib88","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3748\/wjg.14.2139","article-title":"MUC1 and colorectal cancer pathophysiology considerations","volume":"14","author":"Niv","year":"2008","journal-title":"World J. Gastroenterol."},{"issue":"1\u20133","key":"10.1016\/j.prp.2026.156645_bib89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12026-013-8451-6","article-title":"Mechanisms of antitumor and immune-enhancing activities of MUC1\/sec, a secreted form of mucin-1","volume":"57","author":"Ilkovitch","year":"2013","journal-title":"Immunol. Res."},{"issue":"February","key":"10.1016\/j.prp.2026.156645_bib90","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.biopha.2018.08.109","article-title":"Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates","volume":"107","author":"Guo","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib91","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1212\/WNL.0b013e3181ea1597","article-title":"Physical activities and future risk of Parkinson disease","volume":"75","author":"Xu","year":"2010","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22126567","article-title":"Muc1: Structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib93","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib94","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2019.10.003","article-title":"Microbe\u2013MUC1 Crosstalk in Cancer-Associated Infections","volume":"26","author":"Bose","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"August","key":"10.1016\/j.prp.2026.156645_bib95","article-title":"A review on development of MUC1-based cancer vaccine","volume":"132","author":"Gao","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib96","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: Function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"159","key":"10.1016\/j.prp.2026.156645_bib97","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0149-2020","article-title":"The role of mucin 1 in respiratory diseases","volume":"30","author":"Ballester","year":"2021","journal-title":"Eur. Respir. Rev."},{"issue":"APR","key":"10.1016\/j.prp.2026.156645_bib98","first-page":"1","article-title":"The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation","volume":"9","author":"Dhar","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"16","key":"10.1016\/j.prp.2026.156645_bib99","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1074\/jbc.M011248200","article-title":"Transgenic MUC1 Interacts with Epidermal Growth Factor Receptor and Correlates with Mitogen-activated Protein Kinase Activation in the Mouse Mammary Gland","volume":"276","author":"Schroeder","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"1\u20132","key":"10.1016\/j.prp.2026.156645_bib100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2005.12.021","article-title":"Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16","volume":"373","author":"Duraisamy","year":"2006","journal-title":"Gene"},{"issue":"10","key":"10.1016\/j.prp.2026.156645_bib101","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1021\/acs.jproteome.7b00246","article-title":"Glucose limitation alters glutamine metabolism in MUC1- overexpressing pancreatic cancer cells","volume":"16","author":"Gebregiworgis","year":"2017","journal-title":"J. Proteome Res."},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib102","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/1541-7786.MCR-16-0233","article-title":"MUC1-C represses the Crumbs complex polarity factor CRB3 and downregulates the Hippo pathway","volume":"14","author":"Alam","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib103","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.bbadis.2017.03.023","article-title":"Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase","volume":"1863","author":"Gibier","year":"2017","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061288","article-title":"Mucins: The old, the new and the promising factors in hepatobiliary carcinogenesis","volume":"20","author":"Kasprzak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms8050785","article-title":"Key bacteria in the gut microbiota network for the transition between sedentary and active lifestyle","volume":"8","author":"Castellanos","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.prp.2026.156645_bib106","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu. Rev. Physiol."},{"issue":"26","key":"10.1016\/j.prp.2026.156645_bib107","doi-asserted-by":"crossref","first-page":"12820","DOI":"10.1016\/S0021-9258(18)37632-4","article-title":"A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats","volume":"263","author":"Gendler","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib108","first-page":"407","article-title":"The epithelial mucin, MUC1, of milk, mammary gland and other tissues","volume":"1241","author":"Patton","year":"1995","journal-title":"BBA - Rev. Biomembr."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-01899-8","article-title":"Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling","volume":"21","author":"Khodabakhsh","year":"2021","journal-title":"Cancer Cell. Int."},{"issue":"39","key":"10.1016\/j.prp.2026.156645_bib110","doi-asserted-by":"crossref","first-page":"33374","DOI":"10.1074\/jbc.M506047200","article-title":"The MUC1 SEA module is a self-cleaving domain","volume":"280","author":"Levitin","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.prp.2026.156645_bib111","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2012.158","article-title":"MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches","volume":"32","author":"Kufe","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/br.2020.1395","article-title":"Luteolin alters muc1 extracellular domain, st antigen, adam-17, il-8, il-10 and nf-\u03bab expression in helicobacter pylori-infected gastric cancer crl-1739 cells: A preliminary study","volume":"14","author":"Radziejewska","year":"2020","journal-title":"Biomed. Rep."},{"issue":"January","key":"10.1016\/j.prp.2026.156645_bib113","article-title":"Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design","volume":"47","author":"Beckwith","year":"2020","journal-title":"Semin. Immunol."},{"issue":"23","key":"10.1016\/j.prp.2026.156645_bib114","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1039\/C6CS00858E","article-title":"Principles of mucin structure: Implications for the rational design of cancer vaccines derived from MUC1-glycopeptides","volume":"46","author":"Mart\u00ednez-S\u00e1ez","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"18","key":"10.1016\/j.prp.2026.156645_bib115","doi-asserted-by":"crossref","first-page":"10279","DOI":"10.1111\/jcmm.15684","article-title":"Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"3\u20134","key":"10.1016\/j.prp.2026.156645_bib116","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib117","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s11033-011-1144-0","article-title":"Regulation of carcinoembryonic antigen release from colorectal cancer cells","volume":"39","author":"Pakdel","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib118","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3393\/ac.2019.11.13","article-title":"A review of the role of carcinoembryonic antigen in clinical practice","volume":"35","author":"Hall","year":"2019","journal-title":"Ann. Coloproctol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib119","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1245\/s10434-015-5014-1","article-title":"Evaluating the Prognostic Role of Elevated Preoperative Carcinoembryonic Antigen Levels in Colon Cancer Patients: Results from the National Cancer Database","volume":"23","author":"Becerra","year":"2016","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib120","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11605-017-3391-4","article-title":"Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer","volume":"21","author":"Spindler","year":"2017","journal-title":"J. Gastrointest. Surg."},{"issue":"10","key":"10.1016\/j.prp.2026.156645_bib121","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1245\/s10434-009-0651-x","article-title":"Prognostic value of postoperative CEA clearance in rectal cancer patients with high preoperative CEA levels","volume":"16","author":"Kim","year":"2009","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-34855-9","article-title":"Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer","volume":"13","author":"Aldilaijan","year":"2023","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.prp.2026.156645_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.jksus.2021.101613","article-title":"Frizzled receptors (FZD) play multiple cellular roles in development, in diseases, and as potential therapeutic targets","volume":"33","author":"Alrefaei","year":"2021","journal-title":"J. King Saud. Univ. - Sci."},{"issue":"7","key":"10.1016\/j.prp.2026.156645_bib124","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1593\/neo.08320","article-title":"Frizzled-7 as a potential therapeutic target in colorectal cancer","volume":"10","author":"Ueno","year":"2008","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib125","article-title":"Cancer chemoprevention through Frizzled receptors and EMT","volume":"12","author":"Sompel","year":"2021","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051543","article-title":"Frizzled receptors as potential therapeutic targets in human cancers","volume":"19","author":"Zeng","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib127","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jhep.2013.07.001","article-title":"Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs","volume":"59","author":"Pez","year":"2013","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.stemcr.2015.03.003","article-title":"Frizzled7 functions as a Wnt receptor in intestinal epithelial Lgr5+ stem cells","volume":"4","author":"Flanagan","year":"2015","journal-title":"Stem Cell. Rep."},{"issue":"16","key":"10.1016\/j.prp.2026.156645_bib129","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1073\/pnas.1618293114","article-title":"Unsaturated fatty acyl recognition by Frizzled receptors mediates dimerization upon Wnt ligand binding","volume":"114","author":"Nile","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.prp.2026.156645_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2004-5-7-234","article-title":"The Frizzled family: receptors for multiple signal transduction pathways Gene organization and evolutionary history Characteristic structural features","volume":"5","author":"Huang","year":"2004","journal-title":"Genome Biol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib131","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/bph.12364","article-title":"WNT\/Frizzled signalling: Receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3","volume":"171","author":"Dijksterhuis","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib132","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3892\/or.2016.4885","article-title":"Promotion of epithelial-mesenchymal transition by Frizzled2 is involved in the metastasis of endometrial cancer","volume":"36","author":"Bian","year":"2016","journal-title":"Oncol. Rep."},{"issue":"29","key":"10.1016\/j.prp.2026.156645_bib133","doi-asserted-by":"crossref","first-page":"46187","DOI":"10.18632\/oncotarget.10070","article-title":"Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with \u03b2-catenin-dependent and \u03b2-catenin-independent signaling pathways","volume":"7","author":"Zins","year":"2016","journal-title":"Oncotarget"},{"issue":"42","key":"10.1016\/j.prp.2026.156645_bib134","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1523\/JNEUROSCI.1840-15.2015","article-title":"Frizzled3 controls axonal polarity and intermediate target entry during striatal pathway development","volume":"35","author":"Morello","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.prp.2026.156645_bib135","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.biopha.2017.04.028","article-title":"MicroRNA-505 predicts prognosis and acts as tumor inhibitor in cervical carcinoma with inverse association with FZD4","volume":"92","author":"Ma","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.prp.2026.156645_bib136","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1007\/s13277-015-3369-3","article-title":"miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma","volume":"36","author":"Long","year":"2015","journal-title":"Tumor Biol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib137","first-page":"2354","article-title":"FZD6, targeted by miR-21, represses gastric cancer cell proliferation and migration via activating non-canonical wnt pathway","volume":"8","author":"Yan","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"January","key":"10.1016\/j.prp.2026.156645_bib138","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors","volume":"15","author":"Khan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156645_bib139","article-title":"CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib140","first-page":"1","article-title":"The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory\/Recurrent Multiple Myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib141","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"SREP03571","key":"10.1016\/j.prp.2026.156645_bib142","first-page":"2","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib143","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.prp.2026.156645_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib146","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"\u201cCurrent updates on generations, approvals, and clinical trials of CAR T-cell therapy,\u201d","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.prp.2026.156645_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.75660","article-title":"De novo-designed transmembrane domains tune engineered receptor functions","volume":"11","author":"Elazar","year":"2022","journal-title":"Elife"},{"issue":"September 2021","key":"10.1016\/j.prp.2026.156645_bib148","article-title":"Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review","volume":"4","author":"Ahmad","year":"2022","journal-title":"Adv. Cancer Biol. - Metastas-.-."},{"issue":"June","key":"10.1016\/j.prp.2026.156645_bib149","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"9","key":"10.1016\/j.prp.2026.156645_bib150","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.ymthe.2023.08.006","article-title":"LIGHTing CAR T in the tumor microenvironment","volume":"31","author":"Liang","year":"2023","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib151","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"22","key":"10.1016\/j.prp.2026.156645_bib152","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-14-1530","article-title":"Chimeric antigen receptor T-cell therapy to target hematologic malignancies","volume":"74","author":"Kenderian","year":"2014","journal-title":"Cancer Res."},{"issue":"303","key":"10.1016\/j.prp.2026.156645_bib153","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.prp.2026.156645_bib154","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.prp.2026.156645_bib155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.prp.2026.156645_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978195","article-title":"CAR T-cells for colorectal cancer immunotherapy: Ready to go?","volume":"13","author":"Ghazi","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib157","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","article-title":"CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors","volume":"74","author":"Tian","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.prp.2026.156645_bib158","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009960","article-title":"Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells","volume":"12","author":"Qi","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib159","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1186\/s12885-021-08974-3","article-title":"Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response","volume":"21","author":"Sato","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","article-title":"CRISPR\/Cas-based CAR-T cells: production and application","volume":"12","author":"Song","year":"2024","journal-title":"Biomark. Res."},{"issue":"45","key":"10.1016\/j.prp.2026.156645_bib161","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti\u2013CTLA-4 plus anti\u2013PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.prp.2026.156645_bib162","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib163","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.gastro.2019.09.045","article-title":"Therapeutic Targeting of the Colorectal Tumor Stroma","volume":"158","author":"Fridman","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib164","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib165","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"FEB","key":"10.1016\/j.prp.2026.156645_bib166","article-title":"CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.prp.2026.156645_bib167","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/2326-6066.CIR-20-0901","article-title":"Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity","volume":"9","author":"Sakemura","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib168","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.omto.2021.03.003","article-title":"vivo CART cell imaging: Paving the way for success in CART cell therapy","volume":"20","author":"Sakemura","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.prp.2026.156645_bib169","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","article-title":"Improving drug delivery to solid tumors: Priming the tumor microenvironment","volume":"201","author":"Khawar","year":"2015","journal-title":"J. Control. Release"},{"issue":"April","key":"10.1016\/j.prp.2026.156645_bib170","first-page":"1","article-title":"Antigen-specificity measurements are the key to understanding T cell responses","volume":"14","author":"Tippalagama","year":"2023","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.prp.2026.156645_bib171","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-1948","article-title":"A narrative review of tumor heterogeneity and challenges to tumor drug therapy","volume":"9","author":"Zhu","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"690","key":"10.1016\/j.prp.2026.156645_bib172","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2026.156645_bib173","first-page":"43","article-title":"Cytokine release syndrome: Current perspectives,\u201d ImmunoTargets Ther., vol","volume":"8","author":"Murthy","year":"2019"},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib174","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051075","article-title":"Overcoming heterogeneity of antigen expression for effective car t cell targeting of cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib175","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell\u2013inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib176","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib177","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1\u20132 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib178","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s43018-025-00936-z","article-title":"Bispecific chimeric T cell receptors tackle tumor heterogeneity","volume":"6","year":"2025","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib179","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.prp.2026.156645_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2026.156645_bib181","doi-asserted-by":"crossref","unstructured":"H. Ikeda et al., Immune evasion through mitochondrial transfer in the tumour microenvironment., vol. 638, no. January 2023. Springer US, 2025. doi: 10.1038\/s41586-024-08439-0.","DOI":"10.1038\/s41586-024-08439-0"},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib182","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.trecan.2025.04.002","article-title":"Mitochondrial transfer drives immune evasion in tumor microenvironment","volume":"11","author":"Cai","year":"2025","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib183","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmet.2017.06.004","article-title":"Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors","volume":"26","author":"Andrejeva","year":"2017","journal-title":"Cell. Metab."},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib184","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib185","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.prp.2026.156645_bib186","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib187","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib188","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/pathogens2010071","article-title":"Immune evasion, immunopathology and the regulation of the immune system","volume":"2","author":"Sorci","year":"2013","journal-title":"Pathogens"},{"key":"10.1016\/j.prp.2026.156645_bib189","doi-asserted-by":"crossref","unstructured":"S. Talukdar, L. Emdad, S.K. Das, D. Sarkar, and P.B. Fisher, \u201cEvolving Strategies for Therapeutically Targeting Cancer Stem Cells,\u201d 2016, pp. 159\u2013191. doi: 10.1016\/bs.acr.2016.04.003.","DOI":"10.1016\/bs.acr.2016.04.003"},{"key":"10.1016\/j.prp.2026.156645_bib190","doi-asserted-by":"crossref","unstructured":"G. Sayyar, A. Garab, and G. R\u00f6st, \u201cEvolution into chaos-implications of the trade-off between transmissibility and immune evasion,\u201d vol. 10, no. May 1979, pp. 909\u2013923, 2025, doi: 10.1016\/j.idm.2025.04.003.","DOI":"10.1016\/j.idm.2025.04.003"},{"key":"10.1016\/j.prp.2026.156645_bib191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02569","article-title":"T-cell exhaustion in chronic infections: Reversing the state of exhaustion and reinvigorating optimal protective immune responses","volume":"9","author":"Saeidi","year":"2018","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.prp.2026.156645_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms221910828","article-title":"Improving car t-cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib193","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib194","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: Characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib195","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib196","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf. Open. Immunol."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib197","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"issue":"7786","key":"10.1016\/j.prp.2026.156645_bib198","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"6537","key":"10.1016\/j.prp.2026.156645_bib199","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.prp.2026.156645_bib200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.prp.2026.156645_bib201","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers16162858","article-title":"Strategies for Improving CAR T Cell Persistence in Solid Tumors","volume":"16","author":"Wittling","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib202","first-page":"1","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarr\u00e1n","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib204","first-page":"1","article-title":"No \u4e3b\u89b3\u7684\u5065\u5eb7\u611f\u3092\u4e2d\u5fc3\u3068\u3057\u305f\u5728\u5b85\u9ad8\u9f62\u8005\u306b\u304a\u3051\u308b \u5065\u5eb7\u95a2\u9023\u6307\u6a19\u306b\u95a2\u3059\u308b\u5171\u5206\u6563\u69cb\u9020\u5206\u6790Title","volume":"11","author":"Ummah","year":"2019","journal-title":"Sustain"},{"key":"10.1016\/j.prp.2026.156645_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217771","article-title":"The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency","volume":"626","author":"Bao","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib206","article-title":"Genetically engineered t cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.prp.2026.156645_bib207","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib208","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156645_bib209","first-page":"1","article-title":"A Comprehensive Review on Novel Pathways in Cancer Treatment: Clinical Applications and Future Prospects","volume":"24","author":"Shifana","year":"2024","journal-title":"Curr. Cancer Drug. Targets"},{"issue":"8","key":"10.1016\/j.prp.2026.156645_bib210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jgg.2019.06.007","article-title":"Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells","volume":"46","author":"Gao","year":"2019","journal-title":"J. Genet. Genom."},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib211","article-title":"Recent development in bispecific antibody immunotherapy for hematological malignancies","volume":"212","author":"Han","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib212","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib213","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"issue":"March","key":"10.1016\/j.prp.2026.156645_bib214","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"95","key":"10.1016\/j.prp.2026.156645_bib215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000018","article-title":"Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe","volume":"2","author":"Buechner","year":"2018","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib217","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041003","article-title":"Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"26","key":"10.1016\/j.prp.2026.156645_bib218","first-page":"6269","article-title":"Design and Development of Therapies using Chimeric Antigen","volume":"580","author":"Gianpietro Dotti","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.prp.2026.156645_bib219","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02081","article-title":"Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy","author":"Ouladan","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"December","key":"10.1016\/j.prp.2026.156645_bib220","article-title":"Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers","volume":"31","author":"Chinsuwan","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.prp.2026.156645_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124558","article-title":"The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy","volume":"663","author":"Liu","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.prp.2026.156645_bib222","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cti2.1135","article-title":"EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib223","article-title":"An engineering strategy to target activated EGFR with CAR T cells","volume":"4","author":"Dobersberger","year":"2024","journal-title":"Cell. Rep. Methods"},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib224","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70139","article-title":"Routine Monitoring of CAR-T-Cells Expansion and Persistence in Patients With Aggressive Large B-Cell Lymphoma by Flow Cytometry: A Single-Center Experience","volume":"43","author":"Zduniak","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156645_bib225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib226","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-026-02647-0","article-title":"Biomarker-empowered precision navigation of CAR-T cell therapy","volume":"25","author":"Wang","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156645_bib227","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2025.102548","article-title":"Advances in single-cell omics: Transformative applications in basic and clinical research","volume":"95","author":"Inayatullah","year":"2025","journal-title":"Curr. Opin. Cell. Biol."},{"key":"10.1016\/j.prp.2026.156645_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116711","article-title":"From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy","volume":"239","author":"Wijnen","year":"2026","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib229","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1186\/s40001-025-03003-6","article-title":"Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives","volume":"30","author":"Zafar","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100102","article-title":"Identification of cell surface targets for CAR-T cell therapies and antibody\u2013drug conjugates in breast cancer","volume":"6","author":"Schettini","year":"2021","journal-title":"ESMO Open."},{"issue":"17","key":"10.1016\/j.prp.2026.156645_bib231","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156645_bib232","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1735741","article-title":"A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors","volume":"17","author":"Bertucci","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156645_bib233","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clicom.2026.03.002","article-title":"Single-cell multiomics in clinical immunology: Revolutionizing immune profiling","volume":"9","author":"Chowdhury","year":"2026","journal-title":"Clin. Immunol. Commun."},{"key":"10.1016\/j.prp.2026.156645_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113971","article-title":"Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells","volume":"147","author":"Wang","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156645_bib236","article-title":"Novel and effective tandem CD38 and CD19 targeting CAR-T cells inhibit hematological tumor immune escape","volume":"411\u2013412","author":"Liu","year":"2025","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.prp.2026.156645_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.04.063","article-title":"Sequential CD19-20 CAR T-cell therapy for refractory\/relapsed diffuse large B-cell lymphoma","author":"Xue","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.prp.2026.156645_bib238","article-title":"Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial","author":"Zeng","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.prp.2026.156645_bib239","unstructured":"A. Studies, CD19. CAR-T cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy. 2024."},{"key":"10.1016\/j.prp.2026.156645_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.03.001","article-title":"Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy","author":"Yang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2026.156645_bib241","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114113","article-title":"Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells","volume":"148","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib242","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clml.2024.10.003","article-title":"BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma","volume":"25","author":"Rashid","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.prp.2026.156645_bib243","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101256","article-title":"Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma","volume":"70","author":"Yue","year":"2025","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib244","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in Multiple Myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib245","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.prp.2026.156645_bib246","doi-asserted-by":"crossref","unstructured":"\u201cTumor immunology CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular,\u201d pp. 712\u2013724, 2020, doi: 10.1002\/eji.201948457.","DOI":"10.1002\/eji.201948457"},{"key":"10.1016\/j.prp.2026.156645_bib247","article-title":"J o u r n a l o f C a n c e r A long way to the battlefront","volume":"10","author":"Wang","year":"2019","journal-title":"CAR T Cell. Ther. Solid. Cancers"},{"key":"10.1016\/j.prp.2026.156645_bib248","doi-asserted-by":"crossref","unstructured":"Y. Wang, R. Harrison, L. Liu, L. Zhu, and Y. Situ, \u201cand safety,\u201d no. December, 2024, doi: 10.1063\/5.0073746.","DOI":"10.1063\/5.0073746"},{"key":"10.1016\/j.prp.2026.156645_bib249","doi-asserted-by":"crossref","unstructured":"K.C. Vogt et al., \u201cMicroenvironment actuated CAR T cells improve solid tumor efficacy without toxicity,\u201d vol. 3403, no. January, 2025, doi: 10.1126\/sciadv.ads3403.","DOI":"10.1126\/sciadv.ads3403"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib250","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2026.156645_bib251","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/intimm\/dxy042","article-title":"Immune suppression and reversal of the suppressive tumor microenvironment","volume":"30","author":"Shimizu","year":"2018","journal-title":"Int. Immunol."},{"issue":"January","key":"10.1016\/j.prp.2026.156645_bib252","article-title":"Reverting Immune Suppression to Enhance Cancer Immunotherapy","volume":"9","author":"Guerrouahen","year":"2020","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.prp.2026.156645_bib253","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/0008-5472.CAN-23-0230","article-title":"Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2026.156645_bib254","first-page":"1","article-title":"Endoscopic Management of a Tubulovillous Adenoma Within a Diverticulum: Report of a Case and Review of Literature","volume":"12","author":"Hawa","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.prp.2026.156645_bib255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-024-04790-w","article-title":"Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective","volume":"40","author":"Kaviyarasan","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.prp.2026.156645_bib256","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/BTT.S291768","article-title":"Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biol. Targets Ther."},{"issue":"September","key":"10.1016\/j.prp.2026.156645_bib257","first-page":"1","article-title":"ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights","volume":"15","author":"Ali","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.prp.2026.156645_bib258","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"issue":"C","key":"10.1016\/j.prp.2026.156645_bib259","article-title":"Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy","volume":"24","author":"Carcopino","year":"2024","journal-title":"Immuno-Oncol. Technol."},{"issue":"4","key":"10.1016\/j.prp.2026.156645_bib260","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell."},{"issue":"674","key":"10.1016\/j.prp.2026.156645_bib261","first-page":"1","article-title":"Demonstrate Enhanced Homing and E ffi cacy against Several Solid Malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.prp.2026.156645_bib262","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.prp.2026.156645_bib263","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer SYSTEMATIC REVIEW: COMBINATION THERAPY IN COMBATING CANCER BACKGROUND","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.prp.2026.156645_bib264","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.prp.2026.156645_bib265","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy: implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:35:08Z","timestamp":1788762908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":265,"alternative-id":["S0344033826002980"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156645","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156645"}}